Form 4: Ventyx Biosciences Director Somu Subramaniam Granted 40,000 Stock Options

Ventyx Biosciences, Inc. director Somu Subramaniam was granted 40,000 stock options with an exercise price of $2.25, vesting based on continued service.

Summary

• Director Somu Subramaniam of Ventyx Biosciences, Inc. (VTYX) was granted 40,000 stock options.
• The options have an exercise price of $2.25 per share.
• The grant date for these options was June 5, 2025.
• The options expire on June 5, 2035.
• The options will vest on the earlier of the one-year anniversary of the grant date or the day prior to the next Annual Meeting of Stockholders, contingent on continued service as a Service Provider as defined in the Issuer's 2021 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and a long-term incentive for the director. It's a standard compensation practice, hence not extremely positive, but certainly not negative.

Positives

• The grant of stock options to a director indicates alignment of interests between the board and shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a substantial long-term incentive for the director.
• The exercise price of $2.25 per share sets a clear baseline for the stock price performance required for the options to be in-the-money.

Risks

• The vesting of the 40,000 stock options is contingent on Somu Subramaniam continuing to be a 'Service Provider' to Ventyx Biosciences, Inc. through the applicable vesting date.
• The financial value of these options to the reporting person is entirely dependent on Ventyx Biosciences' common stock price exceeding the $2.25 exercise price in the future.

Future Outlook

The stock options granted to Director Somu Subramaniam are designed to incentivize long-term commitment and performance, with vesting tied to continued service as a 'Service Provider' and the company's future stock price performance relative to the $2.25 exercise price. This aligns the director's financial interests with the company's long-term success.

Industry Context

This Form 4 filing reflects a common practice in the biotechnology and pharmaceutical industry where equity incentives, such as stock options, are utilized to attract, retain, and motivate key personnel, including directors, by aligning their financial interests with the long-term success and shareholder value creation of the company. Such grants are a standard component of executive and board compensation packages.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial interests with shareholder value creation, potentially leading to better long-term performance. However, it also represents potential future dilution if the options are exercised.
• Employees: While not directly impacting all employees, this grant is part of the company's broader equity incentive framework, which can influence overall compensation philosophy.

Next Steps

• The stock options will vest on the earlier of the one-year anniversary of the grant date (June 5, 2026) or the day prior to the next Annual Meeting of Stockholders.
• The reporting person must continue to be a Service Provider for the options to vest.

Key Dates

Recommendation

Keywords

Ventyx Biosciences, VTYX, Somu Subramaniam, Stock Options, Form 4, Insider Transaction, Equity Incentive Plan, Director Compensation, Vesting